• In February 2025, AbbVie announced that the FDA had approved Emblaveo (aztreonam and avibactam) in combination with ...

for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible ...

Sanctuary Advisors LLC acquired a new position in Iterum Therapeutics plc (NASDAQ:ITRM – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

Fatty pancreas disease, characterized by intra-pancreatic fat deposition, is more prevalent than diabetes, pancreatitis, and ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...

Michael’s elevation came days after AbbVie received FDA approval for their treatment Emblaveo, which targets intra-abdominal infections. As for Gonzalez, he will officially leave the board of ...

It competes with or is similar to, among others: AbbVie just received FDA approval for its intra-abdominal infection treatment. Demand for Skyrizi and Rinvoq boosted the most recent quarterly results.

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for adults with complicated intra-abdominal infections who have limited or no ...